4//SEC Filing
Schroeder Thilo 4
Accession 0001610717-23-000354
CIK 0001628171other
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 8:13 PM ET
Size
14.7 KB
Accession
0001610717-23-000354
Insider Transaction Report
Form 4
Schroeder Thilo
Director
Transactions
- Award
Common Stock
2023-11-09+922,099→ 3,590,313 total(indirect: By Nextech V Oncology S.C.S., SICAV-SIF) - Award
Earn-out Shares
2023-11-09+70,035→ 70,035 total(indirect: By Nextech VI Oncology SCSp)Exp: 2024-12-17→ Common Stock (70,035 underlying) - Award
Common Stock
2023-11-09+535,112→ 1,153,293 total(indirect: By Nextech VI Oncology SCSp) - Award
Earn-out Shares
2023-11-09+120,683→ 120,683 total(indirect: By Nextech V Oncology S.C.S., SICAV-SIF)Exp: 2024-12-17→ Common Stock (120,683 underlying)
Holdings
- 1,553,134(indirect: By Nextech Crossover I SCSP)
Common Stock
Footnotes (6)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.
- [F2]Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F3]Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F4]Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F5]Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech V was allocated the right to acquire an aggregate of 1,085,271 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech V 120,683 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech V has signed a waiver and release waiving its interests in the Earn-out Shares.
- [F6]Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech VI was allocated the right to acquire an aggregate of 629,803 Earn-out Shares. At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech VI 70,035 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech VI has signed a waiver and release waiving its interests in the Earn-out Shares.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001776412
Filing Metadata
- Form type
- 4
- Filed
- Nov 13, 7:00 PM ET
- Accepted
- Nov 14, 8:13 PM ET
- Size
- 14.7 KB